MichaelX

Everything that happens to us is good if we know how to use it ~Vernon Howard

[MichaelX @segmentintender]

@OldCraig Miners are getting $262 per hour. Between all of them, today.

[MichaelX @segmentintender]

@BSVCasey @big_simp Who instructed exchanges to delist "from above" .I'm open to listen if you have some evidence.

[MichaelX @segmentintender]

@BSVCasey @big_simp Inbred? Why do BSV twitter people end up being abusive and insulting so often? Listing coins is an expensive for a business and with such a small amount of hash BSV becomes a risk too.

[MichaelX @segmentintender]

@BSVCasey @big_simp What did BlackRock do to harm BSV?

[MichaelX @segmentintender]

@big_simp @BSVCasey The people who ran exchanges said it was a reason. All I'm saying rather than play victim we could just accept it was a direct consequence of being attacked. If you don't attack people they may leave you alone.

[MichaelX @segmentintender]

@TRHLofficial Axios is not a good source

[MichaelX @segmentintender]

@big_simp @BSVCasey Lol.

[MichaelX @segmentintender]

@big_simp @BSVCasey The BSV community has nurtured a victim mentality. Most of the problems were self inflicted.

[MichaelX @segmentintender]

@BSVCasey Go on. Begin. Seriously it seems people want to make up excuses and blame people outside BSV if things don't work out.

[MichaelX @segmentintender]

@Nisey2026

[MichaelX @segmentintender]

@scientificecon They can steal Tether because the US govt made Tether put a backdoor in the code.

[MichaelX @segmentintender]

@big_simp This is another story someone made up that doesn't match what we see in the real world.

[MichaelX @segmentintender]

@big_simp The evidence is against that. BTC is $75k. It has no utility.

[محمدباقر قالیباف | MB Ghalibaf @mb_ghalibaf]

۱-ما امتیازات را نه با گفتگو، بلکه با موشک‌‌ها می‌گیریم، در مذاکره فقط آن‌ها را تفهیم می‌کنیم.

۲- هیچ اعتمادی به تضمین‌ها و حرف‌ها نداریم، فقط رفتارها معیار است. اقدامی پیش از اقدام طرف مقابل انجام نخواهد شد.

۳-پیروز هر توافق، کسی است که از فردای آن بهتر برای جنگ آماده شود.

[MichaelX @segmentintender]

@PhotoKuro_ The price needs to go up to get attention, but for BSV it may be too late.

[Nicolas Hulscher, MPH @NicHulscher]

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal

84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.

Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.

The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)

Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.

Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.

This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.

With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.

In the meantime, many cancer patients are exercising their right to try.

@twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson